Compare SSL & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSL | ICUI |
|---|---|---|
| Founded | 1950 | 1984 |
| Country | South Africa | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.2B |
| IPO Year | N/A | 1992 |
| Metric | SSL | ICUI |
|---|---|---|
| Price | $6.17 | $147.75 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $183.60 |
| AVG Volume (30 Days) | ★ 823.7K | 236.9K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $14,028,282,389.00 | $2,320,363,000.00 |
| Revenue This Year | $1.17 | N/A |
| Revenue Next Year | $6.50 | N/A |
| P/E Ratio | $10.55 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.78 | $107.00 |
| 52 Week High | $7.39 | $175.51 |
| Indicator | SSL | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 43.95 | 63.16 |
| Support Level | $5.97 | $141.10 |
| Resistance Level | $6.43 | $148.95 |
| Average True Range (ATR) | 0.12 | 3.94 |
| MACD | -0.04 | -0.36 |
| Stochastic Oscillator | 33.60 | 58.68 |
Sasol Ltd operates as a vertically integrated chemicals and energy company through its two main businesses: the Southern Africa Energy & Chemicals business and the International Chemical business. It generates maximum revenue from the Southern Africa Energy & Chemicals business, which operates integrated value chains with feedstock sourced from the Mining and Gas operating segments. Geographically, the company generates the majority of its revenue from South Africa.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.